Interim results show Brii’s therapeutic HBV vaccine induces immune responseīrii Biosciences Ltd.’s therapeutic vaccine for hepatitis B (HBV), BRII-179 (VBI-2601), induced functional immune responses – inducing broad antibody and T-cell responses – in patients with chronic HBV in a phase II trial that evaluated the vaccine in combination with pegylated interferon-alfa, according to interim results. 2023 financings compare most similarly to 2019, when totals averaged $4.82 billion, and 2022, with $5.07 billion monthly averages. The amount raised in August is higher than the $3.93 billion raised in January and $3.74 billion in February and comparable to April’s $4.19 billion. In August 2023 biopharma companies raised a collective $4.02 billion through 86 transactions, down from the previous seven months’ average of $5.53 billion. Biopharma financings up from last year with $42.75B raised through August 2023 Shares (NASDAQ: CBAY) were trading midday on Sept. The company will be taking the results to regulators globally for advice about next steps. 6 regarding the study called Response in PBC, which met its primary and all key secondary endpoints. Newark, Calif.-based Cymabay disclosed the upbeat news Sept. In the aftermath of Cymabay Therapeutics Inc.’s positive phase III data with seladelpar, the peroxisome proliferator-activated receptor delta agonist in primary biliary cholangitis (PBC), speculation percolated regarding where the drug will fit in the competitive landscape. Cymabay to visit regulators with upbeat phase III data in PBC agreed to pay Verge $25 million in up-front, equity and potential near-term payments, plus as much as $694 million in milestones, to discover and validate up to four new targets for treating the disease over the course of a three-year collaboration. Alexion will select potential targets and keeps an option to license and advance targets through the clinic and into commercialization. There also is potential for downstream royalties. Verge will receive up to $42 million, including up-front, equity and near-term payments from Alexion, Astrazeneca Rare Disease, to identify multiple targets for rare neurodegenerative and neuromuscular diseases. has entered a second big AI deal with a large drug company. Twice as nice: With Alexion, Verge cuts another big AI deal The agreement comes two years after Shape inked a potential $3 billion-plus deal with Roche Holding AG targeting neurodegenerative diseases. Under the terms, Shape gets an undisclosed up-front payment and is eligible for milestones exceeding $1.5 billion, plus royalties. to the table in a gene therapy collaboration that combines the former’s AI-driven AAV platform with the latter’s expertise in ophthalmology. In its second big pharma deal to date, Shape Therapeutics Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |